The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area

  • ID: 4483509
  • Report
  • 55 pages
  • GlobalData
1 of 3
The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area

Summary

The report, "The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area", provides an insight-rich overview of the key events and trends that our analysts expect to occur during 2018. This forward-looking view of the industry identifies key events that will occur across the major therapeutic areas - oncology, immunology, neurology, cardiovascular diseases, metabolic disorders, infectious diseases, and ophthalmology - and provides analyst insight on the potential ramifications of each event.

2018 promises to be a year of continued innovation in the biopharmaceutical industry across therapy areas. In this report, analysts highlight a selection of highly anticipated events, including regulatory approvals, product launches, and clinical trial milestones throughout the year.

Scope

For each therapeutic area, the report includes a timeline of events by quarter and analysis of each event.

Selected events and insights include:
  • Within the oncology space, analysts anticipate that Keytruda will receive FDA approval for adjuvant treatment of melanoma during Q4 2018. In December 2017, the FDA approved Bristol-Myers Squibb’s PD-1 inhibitor Opdivo (nivolumab) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease. Although Keytruda’s head-to-head competitor Opdivo has a head start in this lucrative setting, the adjuvant indication could help close the gap for Keytruda. Analysts expect Keytruda to be a bonafide rival to Opdivo in the adjuvant melanoma setting, with the two drugs splitting the market equally by 2026.
  • Within the immunology space, the author anticipates 2018 BLA submissions of DBV Technologies’ Viaskin Peanut and Aimmune’s AR-101 for peanut allergy (PNA). Armed with positive clinical results from recent pivotal trials, both companies are slated to submit BLAs in 2018 for their respective peanut allergy therapies. Currently available drugs on the market treat the inflammatory symptoms that occur following the accidental exposure to peanut and not the underlying allergy itself. Therefore, these novel immunotherapies will be the first to launch for treating the disease and will revolutionize the field.
  • In the vaccines market, the author anticipates the initial data from Takeda’s pivotal Phase III study evaluating the efficacy and safety of its dengue vaccine candidate, TAK-003, to be announced in H2 2018. The results of this study, which has enrolled over 20,000 children and adolescents across eight dengue-endemic countries, could propel Takeda ahead of rival Sanofi in the dengue vaccine space. Takeda is also investigating the immunogenicity and safety of TAK-003 in non-endemic areas in an ongoing Phase III study (NCT03341637), with initial results also expected in 2018.
Reasons to buy
  • Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2018 by therapeutic area.
  • Gain insight into the potential ramifications of key product approvals, including the effect of their market entrance on the competitive landscape.
  • Understand which clinical trial milestones and data readouts in 2018 are likely to make the greatest impact on treatment paradigms across multiple indications, including both large, well-established disease markets and smaller markets for underserved diseases.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Introduction
Classification of Events
Major Events Year-to-Date: January
Major Events Year-to-Date: February

Oncology
Key Anticipated Events in Oncology and Hematology in 2018
Key Events and Trends to Watch for in Hematological Cancers
Key Events and Trends to Watch for in Gastrointestinal Cancers
Key Events and Trends to Watch for in Genitourinary Cancers
Key Events and Trends to Watch for in Skin Cancers
Key Events and Trends to Watch for in Lung and Brain Cancers

Immunology
Key Anticipated Events in Immunology in 2018
Key Events and Trends to Watch for in Autoimmune Diseases
Key Events and Trends to Watch for in Dermatology
Key Events and Trends to Watch for in Respiratory and Gastrointestinal Diseases
Key Events and Trends to Watch for in Rare and Other Immunological Diseases

Neurology
Top Players in Neurology in 2017
Key Events and Trends to Watch for in Epilepsy
Key Events and Trends to Watch for in Multiple Sclerosis
Key Events and Trends to Watch for in Migraine
Key Events and Trends to Watch for in Parkinson’s Disease and Alzheimer’s Disease
Key Events and Trends to Watch for in Diabetic Neuropathic Pain, Acute Ischemic Stroke, and Amyotrophic Lateral Sclerosis

Cardiovascular and Metabolic Disorders
Key Anticipated Events in CVMD in 2018
Key Events and Trends to Watch for in Osteoporosis and Endometriosis
Key Events and Trends to Watch for in Selected Metabolic Disorders
Key Events and Trends to Watch for in Diabetes
Key Events and Trends to Watch for in Cardiovascular Diseases

Infectious Diseases
Key Anticipated Events in Infectious Diseases in 2018
Key Events and Trends to Watch for in HIV and Hepatitis C
Key Events and Trends to Watch for in Vaccines
Key Events and Trends to Watch for in Antimicrobials

Ophthalmology
Key Anticipated Events in Ophthalmology in 2018
Key Events and Trends to Watch for in Glaucoma
Key Events and Trends to Watch for in Uveitis
Key Events and Trends to Watch for in Age-Related Macular Degeneration
Key Events and Trends to Watch for in Dry Eye Syndrome and Macular Edema

Appendix
Contributors
About
Contact
Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll